Will Going Private Jeopardize Simcere’s Status As A Partner Of Choice For Big Pharma?
This article was originally published in PharmAsia News
Executive Summary
Among U.S-listed Chinese pharmaceutical companies, Simcere has been ahead of the curve in snatching up deals with multinationals. As the Nanjing-based company gets closer to going private, could that status be a concern for potential suitors?
You may also be interested in...
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
Simcere Will Co-Develop Cancer Drugs With BMS; A New R&D Model Between China And U.S.?
SHANGHAI - While reporting strong growth in the third quarter, New York-listed Chinese pharma Simcere focused attention on its recent deal with Bristol-Myers Squibb to co-develop BMS-817378, a small molecule MET/VEGFR-2 inhibitor now in preclinical development
CanSino's Inhaled COVID Vaccine Shows Early Promise As Potential Booster
Early study results show CanSino’s inhaled vaccine for COVID-19 triggered an immune response similar to its injected counterpart.